35Pharma announced the completion of its Series C financing at a US$360M pre-money valuation. 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the treatment of Pulmonary Hypertension, Heart Failure and obesity. 35Pharma leverages its scientific leadership in TGF-beta biology combined with superior protein engineering to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta ligands while sparing beneficial homeostatic ligands.
Stikeman Elliott acted as counsel to 35Pharma with a team that included Jeremy Sculnick, Samantha Allen and Alexandra Vall.
